Exubera expires

Abstract

Get full access to this article

View all access options for this article.

References

Exubera website. http://www.exubera.com/content/Questions.jsp (Accessed November 2007)

Freemantle N. , Blonde L. , Duhot D. et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes . Diabetes Care 2005;28:427-8.

Bellary S. , Barnett AH

Inhaled insulin: overcoming barriers to insulin therapy?

Br J Diabetes Vasc Dis 2006;6:103-08.

Barnett AH , Lange P. , Dreyer M. et al. Long term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract 2007;61:1614-25.

Skyler JS , Jovanovic L. , Klioze S. et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007;30:579-85.

Rosenstock J. , Capelleri JC , Bolinder B. , Gerber RA Patient satisfaction and glycaemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004;27:1318-23.

Ceglia L. , Lau J. , Pittas AG Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006;145:665-75.

Day C. Glycaemic control with advanced new insulins for the treatment of diabetes . Eur Diabetes Nursing 2006;3:117-22.

NICE technology appraisal guidance, 113. Inhaled insulin for the treatment for diabetes (type 1 and 2) National Institute for health and Clinical Excellence. 2006. www.nice.org.uk/TA113 (Accessed Oct 2007)